PARP1 and ovarian cancer: Ovarian cancer cells with homologous recombination deficiencies (HRDs), including breast cancer gene (BRCA) 1/2 mutations, are particularly sensitive to the effects of PARP inhibitors owing to the enhanced cytotoxicity arising from the harmful effect of an additional non-functioning gene, a phenomenon referred to as “synthetic lethality” [13, 14].